The limitations of calcineurin and mTOR inhibitors: New directions for immunosuppressive strategies

被引：16
|
作者：
Kahan, BD [1 ]
机构：
[1] Univ Texas, Sch Med, Div Organ Transplantat, Dept Surg, Houston, TX 77030 USA
来源：
TRANSPLANTATION PROCEEDINGS | 2002年 / 34卷 / 01期
关键词：
D O I：
10.1016/S0041-1345(01)02702-6
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
[No abstract available]
引用
收藏
页码：130 / 133
页数：4
相关论文
共 50 条
  • [1] Conversion from calcineurin inhibitors to mTOR inhibitors as primary immunosuppressive drugs in pediatric heart transplantation
    Asante-Korang, Alfred
    Carapellucci, Jennifer
    Krasnopero, Diane
    Doyle, Abigail
    Brown, Brian
    Amankwah, Ernest
    CLINICAL TRANSPLANTATION, 2017, 31 (10)
  • [2] 2005 immunosuppressive strategies in kidney transplantation: Which role for the calcineurin inhibitors?
    Wong, WC
    Venetz, JP
    Tolkoff-Rubin, N
    Pascual, M
    TRANSPLANTATION, 2005, 80 (03) : 289 - 296
  • [3] Are calcineurin inhibitors safer than mTOR inhibitors?
    Heidi Yeh
    James F. Markmann
    Nature Reviews Nephrology, 2013, 9 : 11 - 13
  • [4] Replacing calcineurin inhibitors with mTOR inhibitors in children
    Sindhi, R
    Seward, J
    Mazariegos, G
    Soltys, K
    Seward, L
    Smith, A
    Kosmach, B
    Venkataramanan, R
    PEDIATRIC TRANSPLANTATION, 2005, 9 (03) : 391 - 397
  • [5] Conversion from calcineurin inhibitors to mTOR inhibitors
    Bodziak, Kenneth A.
    Hrick, Donald E.
    CURRENT OPINION IN ORGAN TRANSPLANTATION, 2007, 12 (04) : 351 - 356
  • [6] TRANSPLANTATION Are calcineurin inhibitors safer than mTOR inhibitors?
    Yeh, Heidi
    Markmann, James F.
    NATURE REVIEWS NEPHROLOGY, 2013, 9 (01) : 11 - 13
  • [7] Pharmacodynamic monitoring of immunosuppressive therapy with calcineurin inhibitors
    Martorell, J
    Millán, O
    Brunet, M
    Campistol, JM
    Faura, A
    Rojo, I
    Vidal, E
    Jiménez, O
    Oppenheimer, F
    Vives, J
    GENES AND IMMUNITY, 2003, 4 : S56 - S56
  • [8] Immunosuppressive minimization with mTOR inhibitors and belatacept
    Diekmann, Fritz
    TRANSPLANT INTERNATIONAL, 2015, 28 (08) : 921 - 927
  • [9] CALCINEURIN INHIBITORS ELIMINATION: WHICH MTOR TO BE CHOSEN?
    Gheith, Osama
    Alotaibi, Torki
    Abdulhalim, Medhat
    Nampoory, Naryanam
    Said, Tarek
    Nair, Prasad
    TRANSPLANT INTERNATIONAL, 2017, 30 : 473 - 473
  • [10] The change of immunosuppressive regimen from calcineurin inhibitors to mammalian target of rapamycin (mTOR) inhibitors and its effect on malignancy following heart transplantation
    Saber-Moghaddam, Niloufar
    Nomani, Homa
    Sahebkar, Amirhossein
    Johnston, Thomas P.
    Mohammadpour, Amir Hooshang
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2019, 69 : 150 - 158
12345